Q1 2026 revenue rose 7.7% YoY to KRW 1,518.8B, with operating income up 158% but a net loss of KRW 44.7B. Major M&A and asset sales were completed, and the group faces significant legal and PF guarantee risks. TG-C clinical trial progress and strong liquidity support long-term growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.